Prescription Drugs

MarketReports.com | Pharmaceuticals & Healthcare |  Prescription Drugs

Global Intravenous (IV) Iron Drugs Market: 2011 Edition Price: $800.00 (€608.69) ($960.00 (€730.42) Including VAT at 20%) Publication Date: Jan-2012 Format: PDF Email Pages: 41 Publisher: Koncept Analytics Iron is one of the most important minerals present in the human body and performs the task of carrying oxygen throughout the body through blood, which is then further utilized by the cells to get energy. Decline in iron can therefore lead to certain major problems. Although oral iron supplements can be used to maintain the iron levels in the body, but oral supplements are chronic treatments and generally have poor absorption, poor compliance, and can have certain side effects. In such cases, IV iron therapy proves out to be the best option. Presently, oral iron dominates the global iron market, holding more than half of the market. But with the increasing use of IV iron, its share is expected to increase and surpass that of oral iron. The global market for IV iron is increasing in the past years. Nephrology remains the largest segment of use for the IV iron therapies, and accounts for more than three-fourths of the overall market. With the ongoing research and development to increase the use of IV iron therapies in other therapeutic areas, including gynaecology, gastroenterology, oncology, chronic heart failures and surgeries, the IV iron market would certainly benefit. There are certain types of IV iron products being marketed and used worldwide, some of which include low molecular weight iron dextran, iron sucrose, ferric gluconate, and ferric carboxylmaltose. The US is the largest IV iron market worldwide, followed by European Union. More than 90% of the dialysis patients receive IV iron therapies, and there is an expected increase in the number of dialysis patients, on the back of ageing population, growing prevalence of hypertension, obesity and diabetes. Therefore, the global IV iron market is likely to increase in the coming years. Vifor Pharma, a part of Galenica Group is the leading company in IV Iron market worldwide, with its two products, Venofre and Ferinject. Some of the other major companies in this sector include Watson Pharmaceuticals (INFeD), and AMAG Pharmaceuticals (Feraheme). The present report analyzes the global IV iron market, with focus on some of the major regional markets, including the US, Europe and Switzerland. Major drivers being discussed in this report are rapidly ageing population, increase use of IV iron in gynecology, and improving results of IV iron in other therapeutic areas including the chronic heart diseases and pre dialysis. Also, the report presents some of the major issues concerning the industry. The leading companies are being profiled, along with their key financials and strategies for growth. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests. Table of Contents/List of Tables/List of Figures

Specialty Pharmaceutical Industry - 2011 Yearbook Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 24-May-2011 Format: PDF Pages: 168 Publisher: GBI Research More...

Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 09-May-2011 Format: PDF Pages: 69 Publisher: GBI Research More...

Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions Price: $3,800.00 (€2,891.26) ($4,560.00 (€3,469.51) Including VAT at 20%) Publication Date: 18-Apr-2011 Please click here for more information or to purchase this report at our partner store Analysis on the global generics market. It includes an overview of drivers and resistors to generic uptake, key generics players, and opportunities for the generics industry.

Pharmaceutical Key Trends 2011 – Biosimilar Market Overview Price: $3,800.00 (€2,891.26) ($4,560.00 (€3,469.51) Including VAT at 20%) Publication Date: 23-Feb-2011 Please click here for more information or to purchase this report at our partner store Comparative analysis of biosimilar drivers and resistors, key players, market access, pricing, and future launches across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.

Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales Overview Price: $3,800.00 (€2,891.26) ($4,560.00 (€3,469.51) Including VAT at 20%) Publication Date: 28-Feb-2011 Please click here for more information or to purchase this report at our partner store An analysis of size and growth of the 12 major pharmaceutical markets (US, Japan, France, Germany, Italy, UK, Australia, Brazil, Russia, India, and China) during 2005–09, and global sales forecasts for the top 50 companies during 2010–15.

Antibacterials: Market Forecast Price: $15,200.00 (€11,565.03) ($18,240.00 (€13,878.03) Including VAT at 20%) Publication Date: 09-Feb-2011 Please click here for more information or to purchase this report at our partner store 10-year forecast for the antibacterial drugs market across the US, Japan and 5EU (France, Germany, Italy, Spain, UK).

Pipeline Insight: Antibacterials Price: $11,400.00 (€8,673.77) ($13,680.00 (€10,408.52) Including VAT at 20%) Publication Date: 17-Feb-2011 Please click here for more information or to purchase this report at our partner store This report provides an in-depth discussion of the antibacterial drugs pipeline. It contains profiles of key late-stage candidates as well as an overview of earlier stage pipeline dynamics, unmet needs and R&D trends.

Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 31-Jan-2011 Format: PDF Pages: 296 Publisher: GBI Research More...

Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 10-Feb-2011 Format: PDF Pages: 195 Publisher: GBI Research More...

Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: 31-Jan-2011 Format: PDF Pages: 107 Publisher: GBI Research More...

Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin Price Single User $3,500.00 Site License $7,000.00 Global Site License $10,500.00 Publication Date: Mar-2011 Format: PDF Pages: 106 Publisher: GBI Research More...

The Future of the Generics Industry Price: $3,835.00 (€2,917.89) ($4,602.00 (€3,501.46) Including VAT at 20%) Publication Date: 26-Aug-2010 Please click here for more information or to purchase this report at our partner store Generics sales have risen consistently over the past decade. Coupled with changes in the geographic and therapeutic make-up of the sector, this has triggered a period of rapid restructuring within the generics industry.

The Future of the Generics Industry: Opportunities, threats and key trends Price: $3,835.00 (€2,917.89) ($4,602.00 (€3,501.46) Including VAT at 20%) Publication Date: 25-Aug-2010 Please click here for more information or to purchase this report at our partner store Demand for generics will continue to increase rapidly during the next five years. Major patent expiries will present generic manufacturers with substantial new targets - including the world's best-selling pharmaceutical brand, Lipitor. Sales of branded copies will rise at double-digit rates in many developing countries, while unbranded, bioequivalent follow-on products will be prescribed, dispensed & consumed more widely in some of the world's biggest markets.

Generics Market Outlook: 2015 Price: $7,600.00 (€5,782.51) ($9,120.00 (€6,939.02) Including VAT at 20%) Publication Date: 15-Oct-2010 Please click here for more information or to purchase this report at our partner store Forecast and historical assessment of the generics market from 2005 to 2015

MarketReports.com | Pharmaceuticals & Healthcare |  Prescription Drugs